Sökning: WFRF:(Andersson Rolf E.) >
Mangafodipir as a c...
-
Karlsson, Jan-ErikLinköpings universitet,Avdelningen för kardiovaskulär medicin,Hälsouniversitetet,Department of Internal Medicine, County Council of Jönköping, Ryhov County Hospital, Jönköping, Sweden
(författare)
Mangafodipir as a cardioprotective adjunct to reperfusion therapy: a feasibility study in patients with ST-segment elevation myocardial infarction
- Artikel/kapitelEngelska2015
Förlag, utgivningsår, omfång ...
-
2015-01-01
-
European Society of Cardiology,2015
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:liu-116549
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-116549URI
-
https://doi.org/10.1093/ehjcvp/pvu021DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:227533964URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Aims The aim of the present study was to examine the feasibility of applying the catalytic antioxidant mangafodipir [MnDPDP, manganese (Mn) dipyridoxyl diphosphate] as a cardioprotective adjunct to primary percutaneous coronary intervention (pPCI) in patients with ST-segment elevation (STE) myocardial infarction (STEMI). Both MnDPDP and a metabolite (Mn dipyridoxyl ethyldiamine) possess properties as mitochondrial superoxide dismutase mimetics and iron chelators, and combat oxidative stress in various tissues and conditions.Methods and resultsThe study tested MnDPDP (n ¼ 10) vs. saline placebo (n ¼ 10), given as a brief intravenous (i.v.) infusion prior to balloon inflation during pPCI in patients with STEMI. Mangafodipir waswell tolerated and did not affect heart rate or blood pressure. Despite longer ischaemic time (205 vs. 144 min, P ¼ 0.019) in theMnDPDPgroup, plasma biomarker releaseswere identical for the two groups. With placebo vs.MnDPDP, mean STE resolutions were 69.8 vs. 81.9% (P ¼ 0.224) at 6 h and 73.1 vs. 84.3% (P ¼ 0.077) at 48 h. Cardiac magnetic resonance revealed mean infarct sizes of 32.5 vs. 26.2% (P ¼ 0.406) andmeanleft ventricular (LV) ejection fractions of 41.8 vs. 47.7% (P ¼ 0.617) with placebovs.MnDPDP.More LVthrombi were detected in placebo hearts (5 of 8) than MnDPDP-treated hearts (1 of 10; P ¼ 0.011).Conclusions Mangafodipir is a safe drug for use as an adjunct to reperfusion therapy. A tendency to benefit of MnDPDP needs confirmation in a larger population. The study revealed important information for the design of a Phase II trial.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
El-Saadi, WalidDepartment of Internal Medicine, County Council of Jönköping, Ryhov County Hospital, Jönköping, Sweden
(författare)
-
Ali, MustafaDepartment of Internal Medicine, County Council of Jönköping, Ryhov County Hospital, Jönköping, Sweden; Department of Radiology, County Council of Jönköping, Jönköping, Sweden
(författare)
-
Puskar, WernerDepartment of Radiology, County Council of Jönköping, Jönköping, Sweden
(författare)
-
Skogvard, PatrikDepartment of Internal Medicine, County Council of Jönköping, Ryhov County Hospital, Jönköping, Sweden
(författare)
-
Engvall, Jan EÖstergötlands Läns Landsting,Linköpings universitet,Avdelningen för kardiovaskulär medicin,Hälsouniversitetet,Fysiologiska kliniken US(Swepub:liu)janen74
(författare)
-
Andersson, RolfLinköpings universitet,Avdelningen för läkemedelsforskning,Hälsouniversitetet(Swepub:liu)rolan40
(författare)
-
Maret, EvaKarolinska Institutet
(författare)
-
Jynge, PerLinköpings universitet,Avdelningen för läkemedelsforskning,Hälsouniversitetet,PledPharma AB, Stockholm, Sweden(Swepub:liu)perjy52
(författare)
-
Linköpings universitetAvdelningen för kardiovaskulär medicin
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:European Heart Journal - Cardiovascular Pharmacotherapy: European Society of Cardiology1:1, s. 39-452055-68372055-6845
Internetlänk
Hitta via bibliotek
Till lärosätets databas